Suvemcitug plus trifluridine/tipiracil for refractory metastatic colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study includes a Phase Ib safety cohort of about 30 participants and a randomized Phase III portion of about 434 participants (total ~464) with unresectable metastatic colorectal adenocarcinoma. In Phase III, participants are randomized 1:1 to receive suvemcitug plus trifluridine/tipiracil or placebo plus trifluridine/tipiracil, with treatment continued until prespecified discontinuation criteria. Investigators will track tumor responses, adverse events, and quality of life during treatment and will follow participants for subsequent therapies and survival after stopping study drug. Eligible patients must have progressed after fluorouracil-, oxaliplatin-, and irinotecan-based chemotherapy and have known RAS status and prior or unsuitable status for anti‑VEGF (and anti‑EGFR if RAS wild-type) therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Confirmed by histological and/or cytological examination as unresectable metastatic colon or rectal adenocarcinoma;
* 2\. At least one measurable tumor lesion (RECIST v1.1);
* 3\. Previously received fluorouracil, oxaliplatin, and irinotecan based chemotherapy; had previously undergone or was unsuitable for anti-VEGF therapy. (For participants with RAS wild-type, had previously undergone or was unsuitable for anti-EGFR therapy.);
* 4\. Refractory metastatic colorectal cancer having progressed on or are intolerant to the last systemic treatment;
* 5\. Good organ and bone marrow function (no administration of hematopoietic growth factors, blood transfusion, or platelets within 14 days before screening hematology test);
* 6\. RAS mutation status confirmed by testing tumor tissue and /or blood sample.

Exclusion Criteria:

* 1\. Having a second active primary malignancy within the past 5 years;
* 2\. Symptomatic central nervous system (CNS) metastases or CNS metastases requiring local CNS-directed therapy (e.g., radiotherapy or surgery) or corticosteroid treatment within 2 weeks prior to the first administration of the study treatment;
* 3\. Any active infection requiring systemic treatment within 2 weeks prior to the initiation of the study treatment;
* 4\. Pleural effusion, pericardial effusion, or ascites that is uncontrolled or has required drainage or medical intervention within 4 weeks prior to the first administration of the study treatment;
* 5\. Received systemic immuno suppressive therapy within 4 weeks prior to randomization (excluding prophylactic use or chronic low-dose steroids \[≤20 mg/day prednisone equivalent dose\]);
* 6\. Currently taking or has recently taken (within 10 days prior to the first dose) aspirin (\>325 mg/day);
* 7\. Active or chronic hepatitis B (HBsAg or HBcAb positive and HBV DNA≥2000 IU/mL or ≥10000 copies/mL) or hepatitis C infection (HCV antibody positive and HCV RNA≥ULN);
* 8\. Clinically significant cardiovascular disease within 6 months prior to the first administration of the study treatment;symptomatic coronary artery disease requiring medication; arrhythmia requiring medication (excluding asymptomatic atrial fibrillation with controlled ventricular rate); QTcF interval \>470 ms at rest state; or uncontrolled hypertension or pulmonary hypertension;
* 9\. Known hereditary or acquired bleeding and thrombotic tendencies (e.g., hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.); clinically significant bleeding events, arterial or deep venous thrombotic events, or superficial venous thrombosis and intermuscular venous thrombosis requiring intervention within 6 months prior to enrollment;
* 10\. Participants with proteinuria (urine protein \>2+ found during screening examinations; or urine protein 2+ with 24-hour urine protein quantification ≥1g/24h);
* 11\. Participants with a history of intestinal obstruction (including incomplete intestinal obstruction) within 1 month prior to enrollment; participants with a history of abdominal fistula, gastrointestinal perforation, or abdominal abscess.

Where it's running

• Fujian Cancer Hospital
  Fuzhou, Fujian, China Recruiting
• Harbin Medical University University Cancer Hospital
  Harbin, Heilongjiang, China Recruiting
• The First Affiliated Hospital of Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting
• Cancer Hospital of Shandong First Medical University
  Jinan, Shandong, China Recruiting
• Tianjin Medical University Cancer Institute and Hospital
  Tianjin, Tianjin Municipality, China Recruiting
• The Second Affiliated Hospital Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Xueyan Li
• Email: lixueyan1@zaiming.com
• Phone: +86-25-85566666

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies

  This trial tests whether combining ivarmacitinib with camrelizumab and fruquintinib can help patients with metastatic colorectal cancer who have progressed after multiple treatments.

  Recruiting Phase 2 Renmin Hospital of Wuhan University · Wuhan, Hubei · NCT07896096

• High‑dose melphalan delivered into the liver followed by trifluridine‑tipiracil plus bevacizumab versus trifluridine‑tipiracil plus bevacizumab alone for liver‑dominant metastatic colorectal cancer

  This test sees if giving high‑dose melphalan directly into the liver followed by trifluridine‑tipiracil plus bevacizumab helps people with liver‑dominant metastatic colorectal cancer more than the drugs alone.

  Recruiting at 20 sites Phase 2 Delcath Systems Inc. · Duarte, California and 19 other locations · NCT06607458

• Combination treatment for advanced colorectal cancer using radiofrequency and chemotherapy

  This study is testing a new combination of radiofrequency treatment and two medications to see if it can help people with advanced colorectal cancer that has spread to the liver.

  Recruiting Charite University, Berlin, Germany · Berlin · NCT05991102

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.